113 related articles for article (PubMed ID: 24373003)
1. Heparin-mediated inhibition of PCR in the accelerated phase of chronic myeloid leukaemia characterised by abundant basophilia.
Satoh Y; Masuda A; Jona M; Nannya Y; Yokota H; Kurokawa M; Yatomi Y
Eur J Haematol; 2014; 92(5):456-7. PubMed ID: 24373003
[No Abstract] [Full Text] [Related]
2. Evaluation of Xpert
Dominy KM; Simon IM; Sorouri-Khorashad J
Int J Lab Hematol; 2021 Feb; 43(1):e31-e34. PubMed ID: 32990400
[No Abstract] [Full Text] [Related]
3. Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies.
Gerrard G; Mudge K; Stewart R; Foskett P; Stevens D; Khorashad JS; Szydlo R; Rezvani K; Marin D; Reid A; Apperley J; Goldman J; Foroni L
Am J Hematol; 2011 Mar; 86(3):313-5. PubMed ID: 21328433
[No Abstract] [Full Text] [Related]
4. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
[TBL] [Abstract][Full Text] [Related]
6. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
7. Standardisation of molecular monitoring for chronic myeloid leukaemia.
Cross NC
Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
[TBL] [Abstract][Full Text] [Related]
8. Can morphological assessment limit the use of specific genetic testing to exclude chronic myeloid leukaemia?
So CC; Wan TS; Yip SF; Ma SK; Lam CC; Chan LC
Br J Haematol; 2007 May; 137(4):377. PubMed ID: 17374140
[No Abstract] [Full Text] [Related]
9. Can absolute basophilia distinguish e1a2 BCR-ABL1 chronic myeloid leukemia from chronic myelomonocytic leukemia?
Langabeer SE; Bhreathnach Ú; Cahill MR; Elhassadi E; Ní Loingsigh S; Conneally E; Enright H
Blood Cells Mol Dis; 2021 Mar; 87():102521. PubMed ID: 33254033
[No Abstract] [Full Text] [Related]
10. Minimal residual disease in chronic myeloid leukaemia patients.
Hochhaus A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):159-78. PubMed ID: 11987922
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Kaeda J; Chase A; Goldman JM
Acta Haematol; 2002; 107(2):64-75. PubMed ID: 11919387
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
13. The biology of chronic myeloid leukemia.
Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian HM
N Engl J Med; 1999 Jul; 341(3):164-72. PubMed ID: 10403855
[No Abstract] [Full Text] [Related]
14. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
[TBL] [Abstract][Full Text] [Related]
15. Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia.
Moravcová J; Nádvorníková S; Lukásová M; Klamová H
Blood; 1999 Nov; 94(10):3609-11. PubMed ID: 10610116
[No Abstract] [Full Text] [Related]
16. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Hur M; Song EY; Kang SH; Shin DH; Kim JY; Park SS; Cho HI
Ann Hematol; 2002 Apr; 81(4):219-23. PubMed ID: 11976825
[TBL] [Abstract][Full Text] [Related]
17. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
18. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Melo JV; Myint H; Galton DA; Goldman JM
Leukemia; 1994 Jan; 8(1):208-11. PubMed ID: 8289491
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
20. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
